Clinical Trial Update: Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery [Phase 1]

View source ↗

Summary

Phase 1 study sponsored by the National Cancer Institute evaluating dasatinib in patients with metastatic or unresectable solid tumors and lymphomas; the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Extranodal Nk T-cell Lymphoma
• Follicular Lymphoma
• Hepatocellular Carcinoma
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Dasatinib (Sprycel) (dasatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia | Phase 1 | Status: COMPLETED